T-1101 (Tosylate)

DRUG3 trials

Sponsors

Taivex Therapeutics Corporation

Conditions

Advanced Refractory Solid Tumors

Phase 1

Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

TerminatedNCT03195764

Taivex Therapeutics CorporationAdvanced Refractory Solid Tumors

Start: 2017-09-14End: 2019-10-23Updated: 2022-11-18

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

CompletedNCT03349073

Taivex Therapeutics CorporationAdvanced Refractory Solid Tumors

Start: 2017-09-14End: 2019-06-24Updated: 2022-11-18

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

CompletedNCT04685473

Taivex Therapeutics CorporationAdvanced Refractory Solid Tumors

Start: 2021-01-07End: 2025-04-11Updated: 2026-07-08

Related Papers

Abstract CT167: Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1/Nek2 inhibitor, in patients with advanced refractory solid tumors

Cancer Research2024-04-051 citations